Top line accelerating.
+9.5% YoY versus +1.7% prior. 3y CAGR +6.7%.
+9.5%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
The Question
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
2 of 2 legendary models say HOLD GSK.
What would legendary investors pay for GSK?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — GSK plc's 34.2% ROE ranks above the S&P 500 median, and D/E 2.75 stays within healthy bounds.
Financial story
Yes — GSK plc's 34.2% ROE shows strong capital efficiency, and its 2.75 debt-to-equity stays within healthy bounds.
Bottom line: GSK is rated BUY by 1 of 2 legendary models, with 1 holding and 0 flagging it overvalued, but earns a C sector grade (56/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
How does GSK compare?
Buffett and Munger evaluate GSK against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
GSK's P/E ratio is 15.5x. 5-year P/E history is in the financials tab.
0 of 2 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
GSK's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
GSK is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
0 of 2 legendary investor models rate GSK a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
See exactly where GSK ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingGSK sits at #32 in Healthcare with a C grade (56/100).